Micro-RNA levels and symptom profile after mild traumatic brain injury: A longitudinal cohort study

Mitra, Biswadev; Reyes, Jonathan; O’Brien, William T.; Surendran, Nanda; Carter, Annie; Bain, Jesse; McEntaggart, Laura; Sorich, Edmond; Shultz, Sandy R.; O’Brien, Terence J.; Willmott, Catherine; Rosenfeld, Jeffrey V.; McDonald, Stuart J.

doi:10.1016/j.jocn.2021.11.021

Cited by 9 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A questionnaire was administered pertaining to factors including demographics (ie, age, gender, height, weight), sporting history (ie, sports played, age they commenced collision sports, age they commenced all sport, years participating in collision sport, years participating in all sports), years of education and history of concussion (number and dates of previous concussions). 4 , 24 - 29 The ‘sport concussion assessment tool’ (SCAT; SCAT3 for 2017/18 players, SCAT5 for 2019 players) assessed symptom severity (maximum 132) at 2-, 6- and 13-days after SRC.…”

Section: Methodsmentioning

confidence: 99%

Decrease in Plasma miR-27a and miR-221 After Concussion in Australian Football Players

et al. 2022

View full text Add to dashboard Cite

Introduction: Sports-related concussion (SRC) is a common form of brain injury that lacks reliable methods to guide clinical decisions. MicroRNAs (miRNAs) can influence biological processes involved in SRC, and measurement of miRNAs in biological fluids may provide objective diagnostic and return to play/recovery biomarkers. Therefore, this prospective study investigated the temporal profile of circulating miRNA levels in concussed male and female athletes. Methods: Pre-season baseline blood samples were collected from amateur Australian rules football players (82 males, 45 females). Of these, 20 males and 8 females sustained an SRC during the subsequent season and underwent blood sampling at 2-, 6- and 13-days post-injury. A miRNA discovery Open Array was conducted on plasma to assess the expression of 754 known/validated miRNAs. miRNA target identified were further investigated with quantitative real-time PCR (qRT-PCR) in a validation study. Data pertaining to SRC symptoms, demographics, sporting history, education history and concussion history were also collected. Results: Discovery analysis identified 18 candidate miRNA. The consequent validation study found that plasma miR-221-3p levels were decreased at 6d and 13d, and that miR-27a-3p levels were decreased at 6d, when compared to baseline. Moreover, miR-27a and miR-221-3p levels were inversely correlated with SRC symptom severity. Conclusion: Circulating levels of miR-27a-3p and miR-221-3p were decreased in the sub-acute stages after SRC, and were inversely correlated with SRC symptom severity. Although further studies are required, these analyses have identified miRNA biomarker candidates of SRC severity and recovery that may one day assist in its clinical management.

show abstract

Section: Methodsmentioning

confidence: 99%

Decrease in Plasma miR-27a and miR-221 After Concussion in Australian Football Players

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The expression of selected miRNAs differed in CT-negative patients-some of them were diagnosed with TBI, but the authors did not identify a separate cohort [56]. It is also worth paying attention to prolonged studies in which miRNA levels are measured over a long period of time [57][58][59][60].…”

Section: Circulating Mirnas Intraumatic Brain Injurymentioning

confidence: 99%

MicroRNAs as Potential Biomarkers of Post-Traumatic Epileptogenesis: A Systematic Review

Vasilieva,

Timechko,

Lysova

et al. 2023

IJMS

View full text Add to dashboard Cite

Structural or post-traumatic epilepsy often develops after brain tissue damage caused by traumatic brain injury, stroke, infectious diseases of the brain, etc. Most often, between the initiating event and epilepsy, there is a period without seizures—a latent period. At this time, the process of restructuring of neural networks begins, leading to the formation of epileptiform activity, called epileptogenesis. The prediction of the development of the epileptogenic process is currently an urgent and difficult task. MicroRNAs are inexpensive and minimally invasive biomarkers of biological and pathological processes. The aim of this study is to evaluate the predictive ability of microRNAs to detect the risk of epileptogenesis. In this study, we conducted a systematic search on the MDPI, PubMed, ScienceDirect, and Web of Science platforms. We analyzed publications that studied the aberrant expression of circulating microRNAs in epilepsy, traumatic brain injury, and ischemic stroke in order to search for microRNAs—potential biomarkers for predicting epileptogenesis. Thus, 31 manuscripts examining biomarkers of epilepsy, 19 manuscripts examining biomarkers of traumatic brain injury, and 48 manuscripts examining biomarkers of ischemic stroke based on circulating miRNAs were analyzed. Three miRNAs were studied: miR-21, miR-181a, and miR-155. The findings showed that miR-21 and miR-155 are associated with cell proliferation and apoptosis, and miR-181a is associated with protein modifications. These miRNAs are not strictly specific, but they are involved in processes that may be indirectly associated with epileptogenesis. Also, these microRNAs may be of interest when they are studied in a cohort with each other and with other microRNAs. To further study the microRNA-based biomarkers of epileptogenesis, many factors must be taken into account: the time of sampling, the type of biological fluid, and other nuances. Currently, there is a need for more in-depth and prolonged studies of epileptogenesis.

show abstract

“…The majority of investigations have concentrated on neuronal and astrocyte-derived proteins (Laverse et al, 2020 ; Meier et al, 2020 ; Mondello et al, 2020 ; Flynn et al, 2021 ; Garland et al, 2021 ; Richard et al, 2021 ). Other potential biomarkers include markers for neuroinflammation and vascular damage (Chiaretti et al, 2008 ; Li et al, 2016 ; Nitta et al, 2019 ) as well as circulating miRNAs that play important roles in gene regulation (Bhomia et al, 2016 ; Lafourcade et al, 2016 ; Di Pietro et al, 2017 , 2018 ; Martinez and Peplow, 2017 ; Mitra et al, 2017 , 2022 ; Qin et al, 2018 ; Das Gupta et al, 2021 ).…”

Section: Extracellular Vesicles and Tbimentioning

confidence: 99%

The evolving role of extracellular vesicles (exosomes) as biomarkers in traumatic brain injury: Clinical perspectives and therapeutic implications

Khan

Asim²,

El‐Menyar³

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

Developing effective disease-modifying therapies for neurodegenerative diseases (NDs) requires reliable diagnostic, disease activity, and progression indicators. While desirable, identifying biomarkers for NDs can be difficult because of the complex cytoarchitecture of the brain and the distinct cell subsets seen in different parts of the central nervous system (CNS). Extracellular vesicles (EVs) are heterogeneous, cell-derived, membrane-bound vesicles involved in the intercellular communication and transport of cell-specific cargos, such as proteins, Ribonucleic acid (RNA), and lipids. The types of EVs include exosomes, microvesicles, and apoptotic bodies based on their size and origin of biogenesis. A growing body of evidence suggests that intercellular communication mediated through EVs is responsible for disseminating important proteins implicated in the progression of traumatic brain injury (TBI) and other NDs. Some studies showed that TBI is a risk factor for different NDs. In terms of therapeutic potential, EVs outperform the alternative synthetic drug delivery methods because they can transverse the blood–brain barrier (BBB) without inducing immunogenicity, impacting neuroinflammation, immunological responses, and prolonged bio-distribution. Furthermore, EV production varies across different cell types and represents intracellular processes. Moreover, proteomic markers, which can represent a variety of pathological processes, such as cellular damage or neuroinflammation, have been frequently studied in neurotrauma research. However, proteomic blood-based biomarkers have short half-lives as they are easily susceptible to degradation. EV-based biomarkers for TBI may represent the complex genetic and neurometabolic abnormalities that occur post-TBI. These biomarkers are not caught by proteomics, less susceptible to degradation and hence more reflective of these modifications (cellular damage and neuroinflammation). In the current narrative and comprehensive review, we sought to discuss the contemporary knowledge and better understanding the EV-based research in TBI, and thus its applications in modern medicine. These applications include the utilization of circulating EVs as biomarkers for diagnosis, developments of EV-based therapies, and managing their associated challenges and opportunities.

show abstract

Micro-RNA levels and symptom profile after mild traumatic brain injury: A longitudinal cohort study

Cited by 9 publications

References 25 publications

Decrease in Plasma miR-27a and miR-221 After Concussion in Australian Football Players

Decrease in Plasma miR-27a and miR-221 After Concussion in Australian Football Players

MicroRNAs as Potential Biomarkers of Post-Traumatic Epileptogenesis: A Systematic Review

The evolving role of extracellular vesicles (exosomes) as biomarkers in traumatic brain injury: Clinical perspectives and therapeutic implications

Contact Info

Product

Resources

About